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This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m2 administered
as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refrac-
tory aggressive non-Hodgkin’s lymphoma. Patients were divided into two cohorts: those with non-cutaneous
peripheral T-cell lymphoma (n=34) and those with other lymphomas (n=33). Efficacy was evaluated using the
International Working Group criteria (1999). Of the 29 evaluable patients with non-cutaneous peripheral T-cell lym-
phoma, six had a response (overall response rate 20.7%; 95% confidence interval, 8.0%-39.7%), including two
complete responses and four partial responses. No responses occurred in the 30 evaluable patients with other lym-
phomas (including 27 B-cell lymphomas). The most common plitidepsin-related adverse events were nausea,
fatigue and myalgia (grade 3 in <10% of cases). Severe laboratory abnormalities (lymphopenia, anemia, thrombo-
cytopenia, and increased levels of transaminase and creatine phosphokinase) were transient and easily managed by
plitidepsin dose adjustments. The pharmacokinetic profile did not differ from that previously reported in patients
with solid tumors. In conclusion, plitidepsin monotherapy has clinical activity in relapsed/refractory T-cell lym-
phomas. Combinations of plitidepsin with other chemotherapeutic drugs deserve further evaluation in patients
with non-cutaneous peripheral T-cell lymphoma. (clinicaltrials.gov identifier: NCT00884286)
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ABSTRACT
Introduction 
Non-Hodgkin’s lymphomas (NHL) are a group of lymphoid
neoplasms that rank among the ten most common types of
cancer. There were an estimated 65,540 newly diagnosed
cases and ~19,500 deaths from this malignancy in the United
States in 2010.1 In the European Union, about 74,000 new
cases were diagnosed and ~31,000 patients died due to the
disease in 2008.2 Most NHL (85-90%) are precursor or mature
B-cell lymphomas, whereas the remaining 10-15% are pre-
cursor or mature T-cell lymphomas. Over the last decade,
there have been improvements in the outcome and survival
of patients with B-cell NHL, as a result of increasing the doses
of active cytotoxic drugs and adding the anti-CD20 mono-
clonal antibody rituximab to chemotherapy.3 In contrast,
peripheral T-cell lymphomas (PTCL) are still associated with
poorer response rates and prognosis compared to B-cell lym-
phoma.4,5 The median overall survival of PTCL patients after
anthracycline-based chemotherapy ranges between 20 and
34 months, with a 4- to 5-year overall survival rate between
28% and 38%.6-8 Hence, new compounds for treating
relapsed aggressive NHL, especially PTCL, constitute a truly
unmet medical need.
Plitidepsin is a cyclic depsipeptide originally isolated from
the Mediterranean tunicate Aplidium albicans and currently
produced by chemical synthesis. Plitidepsin has shown activ-
ity against several human malignant cell lines, including
leukemias9,10 and lymphoma.11 Previous phase I studies
showed that a plitidepsin schedule of 1-hour intravenous (i.v.)
infusions given weekly on days 1, 8 and 15 every 4 weeks
was the most convenient for patients with NHL. In addition,
3.2 mg/m2 was defined as the recommended dose for phase II
studies with this schedule.12 The objective of this phase II
clinical trial was to evaluate the efficacy, safety and pharma-
cokinetics (PK) of plitidepsin given at this dose and schedule
to adult patients with relapsed or refractory aggressive NHL.  
Design and Methods
Patients were recruited at 14 investigational sites in Spain (n=6),
France (n=4), Italy (n=2), Switzerland (n=1) and Peru (n=1). The study
protocol was approved by the Institutional Review Board of each cen-
ter and was conducted in accordance with the Declaration of Helsinki,
Good Clinical Practice guidelines, and local regulations. Signed
informed consent was obtained from all patients prior to any study-
specific procedure. 
Eligibility criteria
Eligibility criteria included: relapsed or refractory, histological-
ly confirmed aggressive NHL, with measurable disease (a bidi-
mensional lesion >2 cm in its longer diameter or >5x109/L lym-
phoma cells circulating in the peripheral blood); recovery from
any non-hematologic toxicities derived from previous therapies;
Eastern Cooperative Oncology Group performance status score
of 0-2; normal left ventricular ejection fraction; and adequate
hematologic, renal, and hepatic function.
Exclusion criteria included: acute lymphoblastic leukemia; cen-
tral nervous system lymphoma; human immunodeficiency virus-
associated lymphoma; concomitant treatment with any anti-pro-
liferative drug; prior doxorubicin at cumulative doses >400
mg/m2, gene therapy with viral vectors, and/or mediastinal radio-
therapy; more than three previous lines of systemic biological
agents or chemotherapies; radiation, radionuclide therapy, sur-
gery or immunosuppressive therapy within 4 weeks;
nitrosoureas, high-dose chemotherapy or extensive beam radia-
tion therapy within 6 weeks; other chemotherapies or biological
agents within 3 weeks; other investigational product within 30
days; history of neoplastic disease (except for non-melanoma
skin cancer, carcinoma in situ, or any other cancer curatively treat-
ed and with no evidence of disease for >10 years); history of sig-
nificant neurological or psychiatric disorders; and other relevant
diseases and medical conditions (e.g., unstable angina, myocar-
dial infarction, valvular heart disease or congestive heart failure,
symptomatic arrhythmia, uncontrolled arterial hypertension
despite optimal therapy, abnormal electrocardiogram, active
infection, significant non-neoplastic liver disease, and uncon-
trolled endocrine disease). Patients also had to use appropriate
contraceptive measures.
Study treatment 
Plitidepsin (PharmaMar, Colmenar Viejo, Madrid, Spain) was
administered through a central or peripheral venous line as a 1-
hour infusion at a dose of 3.2 mg/m2 weekly on days 1, 8 and 15
every 4 weeks. Prophylactic premedication consisted of glucocor-
ticoids (dexamethasone 8 mg i.v.), 5-HT3 antagonists
(ondansetron or equivalent), an H1-receptor antagonist (diphenhy-
dramine hydrochloride 25 mg i.v. or equivalent) and an H2-recep-
tor antagonist (ranitidine 50 mg i.v.). Therapeutic use of
hematopoietic colony-stimulating factors was allowed. No other
antineoplastic therapy was permitted (except for pain manage-
ment, imminent bone fractures or spinal cord compression).
Plitidepsin was administered until progressive disease, clinical
deterioration, or unacceptable toxicity. 
Two dose reductions, at most, were allowed for the following
adverse events: febrile neutropenia; grade 4 neutropenia lasting >5
days; grade 3/4 thrombocytopenia; grade 3/4 nausea/vomiting
despite adequate prophylaxis; grade ≥2 increase in bilirubin; grade
3/4 increase in alanine aminotransferase (ALT) or aspartate amino-
transferase (AST); grade 3/4 increase in alkaline phosphatase;
grade ≥2 muscular toxicity [creatine phosphokinase (CPK)
increase, myalgia and/or muscular weakness]; or any other grade
3/4 non-hematologic toxicity.
Efficacy assessment
Efficacy was assessed every 8 weeks using magnetic resonance
imaging or computed tomography. Treated patients who had at
least one disease assessment were considered evaluable for effica-
cy. The primary efficacy endpoint was the best overall response
rate, defined as the combined rate of complete response, uncon-
firmed complete response and partial response according to the
International Working Group criteria for NHL.13 Time-to-event
endpoints were secondary efficacy endpoints.
Safety assessment
All patients who received at least part of one plitidepsin infusion
were considered evaluable for safety. Adverse events were graded
according to the National Cancer Institute-Common Toxicity
Criteria (NCI-CTC), v. 3.0. Safety was evaluated throughout the
study and for up to 30 days after administration of the last dose of
plitidepsin, and all patients were followed until recovery from any
drug-related adverse events.
Statistical methods
Sample size was based on the primary endpoint (overall
response rate). A Simon’s two-stage design14 was adopted to test
the null hypothesis that P≤0.10 versus the alternative that P≥0.25.
The expected sample size was 40 patients. Sixteen patients were
to be enrolled in the first stage, regardless of their type of lym-
phoma. The study was to be terminated due to lack of efficacy if
no responses occurred in this stage. If at least one response
occurred, the study was to continue until the expected total of 40
evaluable patients had been accrued. 
After the accrual of 42 evaluable patients with relapsed/refrac-
tory lymphoma of any type (including 12 PTCL without cuta-
neous lymphoma), an extension cohort of 16 patients with non-
cutaneous PTCL was recruited. Hence, expected accrual was 58
evaluable patients, 28 of whom with non-cutaneous PTCL. If ≥7
of these 28 patients were responders, the hypothesis that P≥0.350
for non-cutaneous PTCL was to be rejected (b=0.182) and this
schedule would no longer be evaluated in this setting. Otherwise,
if ≥8 non-cutaneous PTCL patients were responders (i.e., an over-
all response rate of 28.6%), the null hypothesis P≥0.150 would be
rejected (α=0.049) and the plitidepsin schedule would be consid-
ered promising in this indication. 
Statistical analyses
Both efficacy and safety analyses were conducted separately for
the cohort of patients with non-cutaneous PTCL and for the
cohort of patients treated for other lymphomas. The primary end-
point (overall response rate) was calculated using descriptive sta-
tistics (95% confidence interval and range). Time to progression,
time to subsequent chemotherapy, progression-free survival and
overall survival were analyzed by the Kaplan-Meier method. Time
to response onset and duration of response were analyzed by cal-
culating the median and range of values. 
Pharmacokinetic analyses
Blood samples (5 mL) for PK evaluation were collected at pre-
defined times at the first plitidepsin infusions (0, 0.5-0.83, 1.42-2,
3-4, 5.5-8.5, 20-33 and 168 hours after the start of the infusion)
from patients recruited into the second stage of the study (i.e.,
excluding the 16 patients recruited into the first stage, regardless
of lymphoma type). Blood samples were taken from the arm not
receiving the infusion. A 3-mL aliquot of whole blood was stored
at -20ºC. Whole blood concentrations of plitidepsin were deter-
mined using a validated high performance liquid chromatography
system coupled with electrospray ionization tandem mass spec-
trometry (HPLC-MS/MS) method.15 Complete concentration-time
profiles of plitidepsin were analyzed by standard non-compart-
mental methods.
Results
Patients’ characteristics
Non-cutaneous peripheral T-cell lymphomas
Thirty-four patients were enrolled (Table 1). Twenty-
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three (67.6%) had stage III-IV disease at diagnosis. All had
refractory (n=18, 52.9%) or relapsed (n=16, 47.1%) dis-
ease at baseline, 16 (47.1%) had extranodal disease and
seven (20.6%) had bone marrow involvement. All patients
had received prior systemic therapy, with a median of two
lines (range, 1-5 lines) per patient. Other prior therapies
comprised radiotherapy (n=8, 23.5%) and stem cell trans-
plantation (n=9, 26.5%).
Other lymphomas
Thirty-three patients were included in this cohort (Table
1). Twenty-four (72.7%) had stage III-IV disease at diagno-
sis. Most (n=24, 72.7%) had refractory disease at baseline,
while the other nine (27.3%) had relapsed disease.
Eighteen (54.5%) had extranodal disease and seven
(21.2%) had bone marrow involvement. Prior systemic
therapy was given to all patients, with a median of three
lines (range, 1-10 lines) per patient. In addition, prior
radiotherapy was given to 11 patients (33.3%) and seven
underwent stem cell transplantation (21.2%).
Treatment and dosing
Non-cutaneous peripheral T-cell lymphomas
A total of 77 plitidepsin cycles were administered, with
a median of two cycles per patient (range, 1-8 cycles). The
median relative dose intensity was 87.4%. Most patients
(n=21; 65.6%) discontinued the study treatment due to
disease progression (Figure 1). 
Other lymphomas 
A total of 57 plitidepsin cycles were administered, with
a median of 1.5 cycles per patient (range, 1-4 cycles). The
median relative dose intensity was 94.6%. Most patients
(n=28; 87.5%) discontinued the study treatment due to
disease progression (Figure 1). 
Efficacy 
Three patients with non-cutaneous PTCL and two with
other lymphomas were excluded from the efficacy analy-
sis (Figure 1). The reasons for exclusion were no tumor
evaluations during treatment (n=2); lesions not measura-
ble according to International Working Group criteria;
having an active infection at study entry; and wrong diag-
nosis (lung carcinoma instead of aggressive NHL) (n=1
each). Figure 2 shows a waterfall chart of the changes in
tumor size that occurred in 32 patients with bidimensional
measurements taken from the same lesions at baseline and
during treatment with plitidepsin: 16 with non-cutaneous
PTCL and 16 with other lymphomas.
Non-cutaneous peripheral T-cell lymphomas 
Six patients showed an objective response to plitidepsin
(two complete responses and four partial responses; over-
all response rate = 20.7%, 95% CI, 8.0%-39.7%) (Table 2).
The histologies of the six responding patients comprised
angioimmunoblastic T-cell lymphoma (n=3, including
both patients with complete responses) and PTCL (n=3).
Both patients who achieved a complete response had pre-
viously received high-dose therapy and stem cell trans-
plantation: one received eight cycles and achieved long-
term remission (lasting for 27.9 months), and the other
one showed a bone marrow complete morphological
remission for 2.8 months. The median duration of
response was 2.2 months (range, 0-27.9 months), with the
response lasting for >14 weeks in two patients (6.9%); one
patient with partial response developed septic shock unre-
lated to treatment shortly after a response had been docu-
mented and was withdrawn from the study. In addition,
six patients had disease stabilization. The median time to
progression was 1.6 months (95% CI, 1.1-3.0 months), the
median progression-free survival was 1.6 months (95%
CI, 1.1-2.7 months), and the median overall survival was
10.2 months (95% CI, 4.4-24.3 months). The time to pro-
gression was ≥3 months in six patients. 
Other lymphomas 
None of these patients responded to plitidepsin (Table
2). The median time to progression/progression-free sur-
Table 1. Demographic and baseline characteristics of the patients.
Characteristic Non-cutaneous Other 
PTCL lymphomas
(n=34) (n=33)
N. % N. %
Age (years) (median, range) 58 (22-80) 63 (17-79)
Gender
Male 24 70.6 22 66.7
Female 10 29.4 11 33.3
ECOG PS
0-1 27 79.4 24 72.7
2 7 20.6 9 27.3
Type of lymphoma
Mature B-cell neoplasms
Diffuse large B-cell lymphoma - - 20 60.6
Mantle-cell lymphoma - - 5 15.2
Follicular lymphoma - - 3 9.1
Burkitt’s lymphoma - - 1 3.0
Mature T-cell neoplasms
Peripheral T-cell lymphoma NOS 17 50.0 - -
Angioimmunoblastic T-cell lymphoma 9 26.5 - -
Anaplastic large-cell lymphoma, 5 14.7 - -
primary systemic type 
Anaplastic large-cell lymphoma, - - 2 6.1
primary cutaneous type 
Extranodal NK/T-cell lymphoma 3 8.8 - -
Precursor T-cell neoplasms
Precursor T-lymphoblastic lymphoma - - 2 6.1
Ann Arbor Lymphoma Staging at diagnosis 
I 4 11.8 2 6.1
II 7 20.6 6 18.2
III 10 29.4 2 6.1
IV 13 38.2 22 66.7
UK - - 1 3.0
Disease at baseline
Refractory 18 52.9 24 72.7
Relapsed 16 47.1 9 27.3
Sites of disease at baseline
Lymph nodes 30 88.2 27 81.8
Extranodal 16 47.1 18 54.5
Bone marrow 7 20.6 7 21.2
Previous therapy
Radiotherapy 8 23.5 11 33.3
Stem cell transplantation 9 26.5 7 21.2
Systemic therapy 34 100 33 100
Number of previous systemic 2 (1-5) 3 (1-10)
therapy lines (median, range)
PTCL: peripheral T-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance
status; NOS: not otherwise specified; UK: unknown.
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vival was 1.3 months (95% CI, 0.8-1.6 months), and the
median overall survival was 4.5 months (95% CI, 2.7-6.4
months).
Safety
Most treatment-related adverse events were mild/mod-
erate (Table 3). The most common were nausea, fatigue
and myalgia. Seven patients had grade 3/4 treatment-relat-
ed adverse events. These comprised muscle weakness
(n=2), Guillain-Barré syndrome, increased cardiac tro-
ponin I, decreased ejection fraction (all three with an
unknown relationship to treatment), prolonged QTc inter-
val on an electrocardiogram, supraventricular arrhythmia,
tachycardia, myalgia, back pain, injection site reaction,
fatigue and edema (n=1 each). 
The most common severe hematologic abnormalities
were grade 3 anemia and grade 3/4 lymphopenia (Table 3).
All patients with severe anemia and most of those with
severe neutropenia or thrombocytopenia already had
these abnormalities at baseline. No cases of febrile neu-
tropenia were found. Most severe biochemical abnormal-
ities did not reach grade 4. The most common were grade
3 increases in ALT/AST and grade 3/4 increases in CPK; all
these abnormalities were transient and were managed
with dose delays, omissions or reductions, and none
resulted in treatment discontinuation. Other severe bio-
chemical abnormalities were less common and had no
effects on treatment. Of note, three patients with
ALT/AST increases and all those with severe increases in
alkaline phosphatase or bilirubin levels while on pli-
tidepsin already showed these abnormalities at baseline.
Five patients were withdrawn from the study due to treat-
ment-related adverse events: grade 2 CPK increase (n=2);
maculo-papular rash; a combination of hypotension, rig-
ors, injection site reaction and back pain; and asthenia
concomitant with muscular toxicity (n=1 each).
Pharmacokinetics
A total of 23 patients had evaluable PK profiles, and 19
of them had a complete profile (with samples up to 168
hours) after the start of the first plitidepsin infusion. The
PK profile of plitidepsin in NHL patients was character-
ized by a mean clearance of 7.45 L/h, a mean volume of
distribution at steady state (Vss) of 355 L and a mean termi-
nal half-life of 36.5 h. A population PK model consisting of
an open, three-compartment model with linear elimina-
tion and distribution from the central compartment was
appropriate to describe the time course of i.v. plitidepsin
whole blood concentrations in NHL patients. Univariate
analyses found statistically significant direct relationships
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Figure 1. Study flow chart.
of plitidepsin whole blood clearance with baseline hemo-
globin, albumin, b2-microglobulin, body surface area,
body weight and serum creatinine; and of whole blood Vss
with baseline hemoglobin, serum albumin, body surface
area, creatinine and body weight. In the multivariate
analysis, hemoglobin was the only parameter to retain a
statistically significant influence, although its significance
disappeared when serum albumin was added to the
model.
Discussion
This exploratory phase II clinical trial was designed to
evaluate the efficacy, tolerability and PK of plitidepsin at a
dose of 3.2 mg/m2 as a 1-hour infusion given on days 1, 8
and 15 every 4 weeks to adult patients with histologically
confirmed aggressive NHL that had relapsed after stan-
dard or high-dose chemotherapy, or that was refractory to
its more recent chemotherapy. This schedule was evaluat-
ed in two cohorts: patients with non-cutaneous PTCL and
patients with other lymphomas. PTCL is a heterogeneous
form of NHL that is generally associated with a poor clin-
ical outcome. Several drugs have been evaluated as single
agents in phase II trials for PTCL (Table 4). Some (e.g., the
anti-CD52 monoclonal antibody alemtuzumab or the
purine nucleoside nelarabine) have shown antitumor
activity for this indication but have been associated with
significant and unacceptable toxicity and their develop-
ment has, therefore, been discontinued.16,17 In other cases
(e.g., bortezomib, gemcitabine, lenalidomide, denileukin
diftitox, romidepsin, and zanolimumab), overall response
rates ranging between 24% and 55% and good safety pro-
files have been found, but the data currently available are
still inconclusive and need to be confirmed in further clin-
ical trials.18-23 Finally, weekly administration of the antifo-
late pralatrexate for 6 weeks in 7-week cycles produced an
overall response rate of 27% in adults with
relapsed/refractory PTCL (with 12% of response lasting
>14 weeks) while showing a toxicity profile similar to that
of other antifolates. These results were considered as like-
ly predictive of clinical benefit, and in 2009 pralatrexate
was granted accelerated approval for the treatment of
relapsed/refractory PTCL.24 To date, no other drug has
been approved for this indication. 
In the cohort of patients with non-cutaneous PTCL, the
overall response rate to plitidepsin of 20.7% in this phase
II trial was lower than the 28.6% pre-established by the
study protocol to consider this schedule worthy of further
evaluation. However, the finding of two complete
responses in patients who had been pretreated with stem
cell transplantation, which in one case was long-lasting
(more than 27 months) and in the other case included
complete bone marrow remission for 2.8 months, suggests
that plitidepsin may have a role in the management of
non-cutaneous PTCL in combination with other
chemotherapeutic drugs. The short median duration of
response (2.2 months) achieved in this cohort is not sur-
prising, given that the patients were heavily pretreated
(median of 1.5 lines per patient). Of note, the dose of pro-
phylactic dexamethasone given to these patients (8 mg
weekly) was low and unlikely to explain this antitumor
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Figure 2. Waterfall chart of
measurement changes in
tumor size during treatment
with plitidepsin in patients
with measurable disease. In
addition, one patient with
bone marrow involvement
at baseline showed a clear
infiltrate on repeat bone
marrow aspirates and biop-
sies, and was considered to
have achieved a complete
response.
Table 2. Objective tumor response according to International Working
Group criteria in patients with relapsed/refractory non-Hodgkin’s lym-
phoma treated with plitidepsin.
Patient Non-cutaneous Other
response PTCL lymphomas
(n=34) (n=33)
N. % N. %
Complete response 2 5.9 - -
Partial response 4 11.8 - -
Stable disease 6 17.6 6 18.2
Progressive disease 17 50.0 24 72.7
Not evaluable 5 14.7 3 9.1
ORR (95% CI)* 20.7% (8.0-39.7%) .
* Evaluable patients. PTCL: peripheral T-cell lymphoma; ORR: overall response rate; CI:
confidence interval.
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activity. Plitidepsin induces apoptosis of tumor cells
through the induction of early oxidative stress and activa-
tion of the JNK pathway. A preclinical study showed that
plitidepsin combined with the cell cycle blocker gem -
citabine was generally more effective than either drug
alone.25 A phase I clinical trial is currently evaluating this
plitidepsin schedule combined with gemcitabine in
mature non-cutaneous T-cell lymphomas. 
No responses were found in the cohort with other lym-
phomas and, therefore, further evaluation of this pli-
tidepsin schedule in patients with relapsed/refractory B-
cell lymphomas or T-cell lymphomas other than non-cuta-
neous PTCL is not warranted.
Plitidepsin was generally well tolerated and showed
manageable toxicity when given to patients with
relapsed/refractory NHL. Most plitidepsin-related adverse
events were mild or moderate. The most common were
nausea, fatigue and myalgia. The most common severe
hematologic abnormalities were grade 3 anemia and grade
3/4 lymphopenia, while the most common severe bio-
chemical abnormalities were grade 3 ALT/AST and grade
3/4 CPK increases. These abnormalities were transient
and were mostly managed by dosing delay, omission or
reduction. The overall safety profile was in accordance
with that reported in a previous phase I clinical trial with
this single-agent schedule in patients with solid tumors.12
Of note, many of the side effects commonly induced by
cytotoxic agents, such as alopecia, mucositis/stomatitis or
clinically relevant myelosuppression, were not characteris-
tic of plitidepsin.
The PK profile of plitidepsin in NHL patients was similar
to that found in patients treated with the same dose and
schedule in a phase I study of patients with solid tumors.12
The time course of plitidepsin whole blood concentrations
in NHL patients was appropriately described by an open,
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Table 3. Worst grade plitidepsin-related adverse events (at least 5% of patients).
Adverse event All patients
(n=64)*
Grade Grade Grade Total
1/2 3 4
N. % N. % N. % N. %
Plitidepsin-related adverse events
Constipation 4 6 . . . . 4 6
Diarrhea 5 8 . . . . 5 8
Fatigue 15 23 . . 1 2 16 25
Muscle cramps 4 6 . . . . 4 6
Muscle weakness 4 6 1 2 1 2 6 9
Myalgia 13 20 1 2 . . 14 22
Nausea 22 34 . . . . 22 34
Pyrexia 5 8 . . . . 5 8
Vomiting 9 14 . . . . 9 14
Hematologic abnormalities
Anemia 51 80 10 16 . . 61 95
Leukopenia 17 27 2 3 2 3 21 33
Lymphopenia 24 38 17 27 4 6 45 71
Neutropenia 9 14 4 6 3 5 16 25
Thrombocytopenia 24 38 4 6 6 9 34 53
Biochemical abnormalities
ALT increased 38 60 14 22 . . 52 83
Amylase increased 3 6 1 2 . . 4 8
AP increased 27 43 2 3 . . 29 46
AST increased  42 67 7 11 . . 49 78
CPK increased 9 15 1 2 4 7 14 23
Creatinine 18 28 1 2 . . 19 30
increased
Total bilirubin 19 31 1 2 . . 20 33
increased
* Patients evaluable for safety. Data shown are number and percentage of patients (based on
patients with available data). Only laboratory abnormalities reaching grade 3 or 4 are shown.
PTCL: peripheral T-cell lymphoma; ALT: alanine aminotransferase; AP: alkaline phosphatase; AST:
aspartate aminotransferase; CPK: creatine phosphokinase. 
Table 4. Results of chemotherapeutic agents tested as single-agent therapies in phase II trials that included patients with relapsed/refractory peripheral
T-cell lymphoma.16-24
Study Drug/schedule and dose N. of patients with PTCL Responses in PTCL ORR Types of response
(%)
Enblad et al.  Alemtuzumab 14 5 / 14 36 3 CR + 2 PR
2004 30 mg i.v. qwk
Czuczman et al. 2007 Nelarabine 8 1 / 8 25 1 PR
1.5 g/m2 i.v. 
on Days 1, 3 and 5 q3wk
Dang et al. Denileukin diftitox 27 13 / 27 48 6 CR + 7 PR
2007 18 mg/kg/d x 5 d q3wk
Zinzani et al. Gemcitabine 20 11 / 20 55 6 CR + 5 PR
2010 1200 mg/m2 i.v. 
on Days 1, 8 and 15 q4wk
Dueck et al. Lenalidomide 25 mg p.o. 23 7 / 23 30 7 PR
2010 on Days 1-21 q4wk
d’Amore et al. Zanolimumab 21 5 / 21 24 2 CRu + 3 PR
2010 980 mg i.v. qwk
Coiffier et al. Romidepsin 14 mg/m2 130 34 / 130 26 19 CR/CRu 
2010 on Days 1, 8 and 15 q4wk + 15 PR
Piekarz et al. Romidepsin 14 mg/m2 31 17 / 31 55 7 CR + 10 PR
2011 on Days 1, 8 and 15 q4wk
O’Connor et al. Pralatretaxe 109 32 / 109 29 12 CR/CRu
2011 30 mg/m2 i.v. qwk for 6 weeks + 1-week rest + 20 PR
Current trial Plitidepsin 3.2 mg/m2 i.v. 29 6 / 29 21 2 CR + 4 PR
on Days 1, 8, 15 q4wk
* Only patients with cutaneous forms of the disease were included. PTCL: peripheral T-cell lymphoma; ORR: objective response rate; i.v.: intravenously; CR: complete response; PR: partial
response; qwk: weekly; q3wk: every 3 weeks; q4wk: every 4 weeks; p.o.: orally; CRu: unconfirmed complete response.
three-compartment population PK model with linear elim-
ination and distribution from the central compartment,
and a non-linear distribution to blood cells. This same
model was defined for plitidepsin in a population PK
meta-analysis of data from 283 patients with advanced
solid tumors who received the drug as monotherapy at
doses ranging from 0.13 to 8.0 mg/m2 and at different
schedules, one of which was the one evaluated in the
present study.26
In conclusion, single-agent plitidepsin has shown antitu-
mor activity and a tolerable safety profile in patients with
relapsed/refractory non-cutaneous PTCL. These results
therefore support the conduct of further clinical trials to
evaluate plitidepsin-containing combined therapies in this
disease setting.
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